Genome-wide association studies (GWAS) have identified abundant genetic susceptibility loci, although they are far less from meeting the previous expectations due to low statistical power and false positive results. Effective statistical methods are required to further improve the analyses of massive GWAS data. Here we presented a new statistic (Robust Reference Powered Association Test, http://drwang.top/gwas.html) to use large public database as reference to reduce concern of potential population stratification. To evaluate the performance of this statistic for various situations, we simulated multiple sets of sample size and frequencies to compute statistical power. Furthermore, we applied our method to several real datasets (psoriasis genome-wide association datasets and schizophrenia genome-wide association dataset) to evaluate the performance. Careful analyses indicated that our newly developed statistic outperformed several previously developed GWAS applications. Importantly, this statistic is more robust than naive merging method in the presence of small control-reference differentiation, therefore likely to detect more association signals.
INTRODUCTION
Genome-wide association studies (GWAS) have been widely applied with the goals to detect genetic variants which contribute to complex traits in the past decade (1) . In general, allele frequencies of genetic variants are compared between cases that are supposed to have a high prevalence of susceptibility alleles and controls that are considered to have a lower prevalence of such alleles. And genomic loci correlated with various traits had been detected using the efficient approaches (2) .
Although GWASs have led to abundant significant findings (3) (4) (5) (6) (7) , a few practical difficulties hinder the discovery of more rare or low-frequency genetic variants. For example, limited sample sizes make it difficult to achieve high statistical power which shows the probability of identifying the latent genetic variants (2, 8) . Besides, difference in genetic background, also known as population stratification, between cases and controls could inflate type I error rate, thereby, leading to increasing level of false positive findings (9) .
Availability of large public datasets contain large amount of useful genetic information. Utilizing large public datasets as reference may increase the sample size and ease the low power brought by insufficient sample size. However, population stratification and genotyping platform differences (10) between public datasets and cases may lead to inflated type I error rate. Our study aim is to appropriately utilize the public datasets to conservatively ameliorate the situation of small samples and low statistical power. In this manuscript, we describe a novel method to properly use public datasets as reference. In particular, we introduce a large public population as reference which has similar genetic background with control group. The null hypothesis was that allele frequency of SNPs among case (ca), control (co) and reference (re) was equal, and that the control and reference might compose a new large reference (co+re). (11) (12) (13) of the SNP between case and control+reference, and ‫‬ h is p-value of 2×2 Fisher exact test (11) (12) (13) of the SNP between control and reference. The T statistic takes differences between control and reference into account, which is more robust than t h ‫‬ or t h .
Specifically, we constructed a new test statistic i mS t h ‫‬
In this manuscript, we present a method to use public datasets as reference in the association analysis. The results of simulation and real data application showed that our new method could increase statistical power. And the online tool (Robust Reference Powered Association Test, http://drwang.top/gwas.html) has been made available.
MATERIAL AND METHODS

Framework of Robust Reference Powered Association Test
Suppose we have three populations: case, control and public data pools, intuitively we want to merge the control and reference population to form a large control pool to gain more power on allele-disease association test. However, we are concerned about the potential population differentiation and genotyping platform difference between control and the reference (10) .
A simplistic way to alleviate such concern is to perform a control (co) vs. reference (re) Fisher exact test (11) . If a p-value is not significant and the control sample size is not too small, then this concern is resolved. However, choosing the significance level is arbitrary and the decision is subjective.
We need an objective version of such procedure to correct the effect of co-re (control vs. reference) difference.
Denote the p-value of 2×2 Fisher exact test (11) (12) (13) ‫‬ are exponentially distributed with parameter 1 (14) . And T is the difference of two exponentially distributed variables, thus T is Laplace distributed as T~Laplace (0, 1) (15). The one side p-value of T is as follow:
From the above formula one can easily see that the ‫‬ h acts as a penalizer/normalizer against t h ‫‬ . Therefore, our new statistic T is more robust than the simple t h ‫‬ method in the presence of small control-reference differentiation. However, in the presence of strong population differentiation or genotyping platform difference, even our correction may not be effective, we therefore need to restrict ‫‬ h to be not significant with a suggested threshold of 0.01.
The psoriasis GWAS datasets
We obtained the psoriasis datasets (16, 17) , 
RESULTS
Results from simulation study
To evaluate the performance of our model for various situations, we simulated six parameters to compute the desired statistical power. The parameters include case sample size, allele frequency in case, control sample size, allele frequency in control, reference sample size and allele frequency in reference.
Six different parameters were set to several typical values to simulate real scenarios. The case and control size were set from small to large. Also, allele frequencies were set from rare to common.
Additionally, we selected two different reference of 10,000 and 100,000 samples. We have selected several representative cases to analyze the whole results of simulations (Table 1) .
First, supposed that the sample size of case, control and reference equaled 500, 500 and 10,000 respectively which were close to the real conditions. And allele frequencies in case, control and reference were initialized to be common (0.15). As indicated in Table 1 , the power of T was a bit higher than power of ca-(co+re), while both were less than false positive rate (alpha=0.05, 0.01, 0.001). When there was small population genetic differentiation between control and reference, allele frequencies in case and control equaled 0.165 while allele frequency in reference was set as 0.15. In this case, the power of T was less than the power of ca-(co+re). Therefore, as mentioned in Method, our new test is more robust than the simple t h ‫‬ method in the presence of small control-reference differentiation.
As shown in Table 1 , false positive results might occur if there was small population genetic differentiation between control and reference while no differentiation between case and control. To evaluate the influence of control size, we simulated different control sizes with the aim to detect the false positive rate under different allele frequencies of case and control (see Additional files 2). We found that the false positive rate of P(T) would decrease when control size was augmented.
Furthermore, P(T)'s power was less than t h ‫‬ 's when the sample size of the controls was five times larger than that of the cases. The false positive results were kept as low as possible when the sample size of the controls was four times larger than that of the cases (see Additional files 2).
When the allele frequency in case was different from that in control, T's power was always higher than power of ca-co. We could find that when there was a slight change of allele frequency in case, the power of T was much higher than power of ca-co, indicating that our method had high sensitivity for
GWAS. When the allele frequency in case was much higher than control's, the power approached to 1 with remarkable increase of T's power. When the allele frequency was rare, we could also draw the same conclusion that our method could keep false positive rate low and drastically increase the statistical power.
Results from the psoriasis GWAS datasets
We applied our newly developed method to two psoriasis genome-wide association (GWAS) (16, 17) datasets to evaluate the performance. SNPs associated with psoriasis that had been reported by other studies. By integrating the results of ref1 and ref2, we found that the SNPs with ref2 as reference were included in the results of ref1. And we presented the novel SNPs of GRU group (Table 2 ) and ADO group (Table 3) . We calculated the genomic inflation factor, also known as lambda (λ). In GRU group, λ of P(T) and t h ‫‬ were (20) . For the ADO group, rs3130573 (P(T) = 1.70E-10) was located in PSORS1C1 (MIM: 613525) gene which was a major susceptibility locus for psoriasis (23) .
Results from the schizophrenia GWAS datasets
We also applied our newly developed method to one schizophrenia GWAS (18) For the schizophrenia GWAS dataset (18) , the typical Fisher exact test did not yield genome-wide significant findings. After the introduction of reference, we found that several novel SNPs were associated with schizophrenia ( Table 4 ). The Manhattan plot (Figure 4 ) clearly showed that before performing our method there were only a few SNPs with p-value below 1e-5 in the bottom figure. And after performing our method, plenty of SNPs came to the fore with p-value between 1e-5 and 1e-8. In addition, there were significant SNPs with p-value below 7e-8, some of which had been reported in previous studies. The SNP rs12140791 is located in NOS1AP (MIM: 605551) gene which is essential for brain development and function and of potential relevance to schizophrenia (24) . The rs17021364
and rs11097407 were reported to be associated with schizophrenia in a genome-wide meta-analysis (25) . The rs35648 (p-value = 9.65E-5) was also reported by a previous large-scale GWAS (26) . The genomic inflation factors were 0.77 and 1.01 for P(T) and P(ca-co) respectively.
DISCUSSION
Associations between SNPs and complex traits were detected by comparing frequencies of alleles in case and control group in GWAS (1) . Several significant SNPs have been identified in classic GWAS studies (27) (28) (29) (30) . However, other SNPs of low frequencies which contribute to the complex traits remain hidden in the false negative results (31) (32) (33) (34) (35) . To identify more novel susceptibility loci, large-scale GWAS is a costly and time-consuming approach. It is necessary to design more sensitive and accurate statistical methods. Interestingly, the results indicated that our method could increase the power which may contribute to detecting more significant SNPs.
Our simulations focused on several representative cases to evaluate the performance of the new model. When the allele frequencies of case, control and reference were equal, the power of T was higher than power of ca-(co+re), while both less than false positive rate. False positive results would be produced in the presence of small population genetic differentiation between control and reference.
However, as the control size increased, the false positive rate of P(T) would be reduced ( Table 1 ). The false positive rate would be controlled well, when the control sample was large enough. What's more, T's power was always higher than power of ca-co, when the allele frequencies of case and control were different, indicating that our method was more robust and had high sensitivity for GWAS.
For the psoriasis genome-wide association (GWAS) datasets (16, 17) , the positive SNPs became more positive and some of the negative SNPs turned to be positive after application of our method. The rescued SNPs, rs1343708 (20) , rs7192 (21), rs20541 (21), rs1051792 (22) , rs2442719 (20) and rs3130573 (23) were identified to be true positive. For the schizophrenia GWAS dataset (18) , typical
Fisher Exact tests produced no significant positive genetic loci. However, our method found that SNPs rs12140791 (24) , rs10753758, rs11097407 (25) , rs17021364 (25) , rs35648 (26) could potentially be associated with schizophrenia. The results indicated that our method could be sensitive to generate more positive SNPs.
In the aforementioned application of our method to the psoriasis genome-wide association (GWAS) genetic datasets (16, 17) , we selected two large public datasets as reference groups (19) . With different references, the model will compute different p-values for the test statistic. In the case of scenario, the p-value is lower than threshold of 0.01, indicating significant differentiation between control and reference, the result would be false positive. In this situation, selecting an appropriate dataset as the reference is the key to obtain better result. In addition, selecting multiple different references is feasible with the online tool. By comparing and integrating the output of different references, reasonable significant P(T) could provide more effective information for SNPs associated with the traits.
Novel SNPs with weak positive signals could be discovered when the sample size of case and control are insufficient in GWAS (2) . With the support of reference database, the new p-value of some false negative genetic loci would decrease significantly down to the threshold. And our test statistic T is more robust than t h ‫‬ as it takes the control-reference difference into account by penalization of ‫‬ h .
To conclude, the new statistic proposed here is effective to discover novel genome-wide significant loci with both small and large sample sizes.
DATA AVAILABILITY
The psoriasis datasets and the schizophrenia dataset can be obtained from the Genetic Association 
